GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Cyclically Adjusted Book per Share

Redhill Biopharma (Redhill Biopharma) Cyclically Adjusted Book per Share : $311.32 (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Redhill Biopharma's adjusted book value per share for the three months ended in Jun. 2023 was $0.881. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $311.32 for the trailing ten years ended in Jun. 2023.

During the past 12 months, Redhill Biopharma's average Cyclically Adjusted Book Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-04-29), Redhill Biopharma's current stock price is $0.433. Redhill Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was $311.32. Redhill Biopharma's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Redhill Biopharma was 1.19. The lowest was 0.01. And the median was 0.14.


Redhill Biopharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Redhill Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Cyclically Adjusted Book per Share Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 315.38 309.52 -

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 314.69 309.52 311.15 311.32 -

Competitive Comparison of Redhill Biopharma's Cyclically Adjusted Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Cyclically Adjusted PB Ratio falls into.



Redhill Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Redhill Biopharma's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book= Book Value per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.881/128.7287*128.7287
=0.881

Current CPI (Jun. 2023) = 128.7287.

Redhill Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201309 88.764 98.790 115.664
201312 74.068 98.326 96.970
201403 169.589 99.695 218.979
201406 154.158 100.560 197.341
201409 136.266 100.428 174.666
201412 113.836 99.070 147.916
201503 136.396 99.621 176.249
201506 869.742 100.684 1,112.003
201509 2,084.194 100.392 2,672.493
201512 189.046 99.792 243.863
201603 1,728.122 100.470 2,214.174
201606 1,540.736 101.688 1,950.444
201609 127.036 101.861 160.544
201612 147.030 101.863 185.809
201703 1,382.411 102.862 1,730.042
201706 113.733 103.349 141.663
201709 79.062 104.136 97.734
201712 84.737 104.011 104.874
201803 68.012 105.290 83.153
201806 48.549 106.317 58.783
201809 62.473 106.507 75.508
201812 72.172 105.998 87.649
201903 59.044 107.251 70.868
201906 44.985 108.070 53.585
201909 32.219 108.329 38.286
201912 68.050 108.420 80.797
202003 24.751 108.902 29.257
202006 36.982 108.767 43.769
202009 30.684 109.815 35.969
202012 14.442 109.897 16.917
202103 45.463 111.754 52.368
202106 25.323 114.631 28.437
202109 8.816 115.734 9.806
202112 6.775 117.630 7.414
202203 -3.976 121.301 -4.219
202206 -7.483 125.017 -7.705
202209 -28.748 125.227 -29.552
202212 -20.773 125.222 -21.355
202303 0.741 127.348 0.749
202306 0.881 128.729 0.881

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Redhill Biopharma  (NAS:RDHL) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Redhill Biopharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.433/311.32
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Redhill Biopharma was 1.19. The lowest was 0.01. And the median was 0.14.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Redhill Biopharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.